As of December 2024, there are no class action lawsuits involving Ozempic. Instead, individuals have filed personal injury lawsuits alleging that Ozempic caused severe gastrointestinal issues, such as gastroparesis and bowel obstruction. In February 2024, the U.S. Judicial Panel on Multidistrict Litigation consolidated these cases into MDL-3094 in the Eastern District of Pennsylvania, with Judge Gene E.K. Pratter presiding.
This multidistrict litigation (MDL) streamlines pretrial proceedings for numerous individual lawsuits sharing common factual questions, enhancing efficiency and consistency. Unlike a class action, where a single lawsuit represents a group with similar claims, an MDL maintains each plaintiff’s case as a separate action, allowing for individual assessments of damages and specific circumstances.
Plaintiffs in these cases allege that Novo Nordisk, the manufacturer of Ozempic, failed to provide adequate warnings about the drug’s potential side effects, leading to significant health complications. Novo Nordisk maintains that these allegations are without merit and stands by the safety and efficacy of their product when used as directed.
The MDL process is ongoing, with discovery and pretrial motions underway. The number of cases continues to grow, reflecting increasing concerns over Ozempic’s safety profile. Individuals who believe they have suffered harm from Ozempic are advised to consult legal counsel to discuss potential claims within the context of the existing MDL.
1-800-870-8910